Antibodies that specifically bind to Aβ oligomers and uses thereof
View Patent ↗The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.
1. An antibody that binds to an Aβ oligomer, wherein the antibody comprises an H chain having the amino acid sequence of SEQ ID NO: 61 and an L chain having the amino acid sequence of SEQ ID NO: 63.
2. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
3. An antibody that binds to an Aβ oligomer and is any one of (1) to (4) below:
(1) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 69 as CDR1, the amino acid sequence of SEQ ID NO: 71 as CDR2, and the amino acid sequence of SEQ ID NO: 73 as CDR3,
and an L chain having the amino acid sequence of SEQ ID NO: 75 as CDR1, the amino acid sequence of SEQ ID NO: 77 as CDR2, and the amino acid sequence of SEQ ID NO: 79 as CDR3;
(2) an antibody that comprises an H chain having the amino acid sequence of SEQ ID NO: 65 as VH;
(3) an antibody that comprises an L chain having the amino acid sequence of SEQ ID NO: 67 as VL; and
(4) an antibody that comprises the H chain (2) of and the L chain of (3).
4. The antibody of claim 3 , wherein the antibody is a chimeric antibody or a humanized antibody.
5. A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.
6. A method for treating cognitive impairment associated with Aβ accumulation in the brain of a subject, which comprises administering the antibody of claim 1 as an active ingredient to a subject in need thereof.
7. A method for treating Alzheimer's disease, which comprises administering the antibody of claim 1 as an active ingredient to a subject in need thereof.
8. A method for suppressing the progression of Alzheimer's disease, which comprises administering the antibody of claim 1 as an active ingredient to a subject in need thereof.
9. A method for suppressing senile plaque formation associated with Aβ accumulation in the brain of a subject, which comprises administering the antibody of claim 1 as an active ingredient to a subject in need thereof.
10. A method for suppressing Aβ accumulation, which comprises administering the antibody of claim 1 as an active ingredient to a subject in need thereof.
11. A method for neutralizing Aβ induced neurotoxicity, which comprises administering the antibody of claim 1 as an active ingredient to a subject in need thereof.
12. A method for inhibiting Aβ amyloid fibril formation, which comprises administering the antibody of claim 1 as an active ingredient to a subject in need thereof.
13. A method for neutralizing Aβ mediated synaptic toxicity, which comprises administering the antibody of claim 1 as an active ingredient to a subject in need thereof.
14. A method for detecting an Aβ oligomer, which comprises detecting an AR oligomer contained in a sample collected from a subject by contacting the sample with the antibody of claim 1 .
15. The method of claim 14 , wherein the sample is blood or cerebrospinal fluid.
16. A method of diagnosing a subject as suffering from or being at risk of developing Alzheimer's disease, which comprises:
(a) contacting a sample collected from the subject with the antibody of claim 1 ; and
(b) measuring the amount of Aβ oligomer in the sample, wherein the subject is determined to suffer from or be at a risk of developing Alzheimer's disease when the amount measured in (b) is higher than that of a healthy individual.
17. The method of claim 16 , wherein the sample is blood or cerebrospinal fluid.
18. A method of diagnosing a subject as suffering from or being at risk of developing Alzheimer's disease, which comprises:
(a) contacting a sample collected from the subject with the antibody of claim 1 and an antibody that binds to an Aβ monomer; and
(b) measuring the ratio of Aβ oligomer to Aβ monomer in the sample, wherein the subject is determined to suffer from or be at a risk of developing Alzheimer's disease when the ratio measured in (b) is higher than that of a healthy individual.
19. The method of claim 18 , wherein the sample is blood or cerebrospinal fluid.
20. A method for treating cognitive impairment associated with Aβ accumulation in the brain of a subject, which comprises the step of administering the antibody of claim 3 as an active ingredient to a subject in need thereof.
21. A method for treating Alzheimer's disease, which comprises the step of administering the antibody of claim 3 as an active ingredient to a subject in need thereof.
22. A method for suppressing the progression of Alzheimer's disease, which comprises the step of administering the antibody of claim 3 as an active ingredient to a subject in need thereof.
23. A method for suppressing senile plaque formation associated with Aβ accumulation in the brain of a subject, which comprises the step of administering the antibody of claim 3 as an active ingredient to a subject in need thereof.
24. A method for suppressing Aβ accumulation, which comprises the step of administering the antibody of claim 3 as an active ingredient to a subject in need thereof.
25. A method for neutralizing Aβ induced neurotoxicity, which comprises the step of administering the antibody of claim 3 as an active ingredient to a subject in need thereof.
26. A method for inhibiting Aβ amyloid fibril formation, which comprises the step of administering the antibody of claim 3 as an active ingredient to a subject in need thereof.
27. A method for neutralizing Aβ mediated synaptic toxicity, which comprises the step of administering the antibody of claim 3 as an active ingredient to a subject in need thereof.
28. A method for detecting an Aβ oligomer, which comprises the step of detecting an Aβ oligomer contained in a sample collected from a subject by contacting the sample with the antibody of claim 3 .
29. The method of claim 28 , wherein the sample is blood or cerebrospinal fluid.
30. A method of diagnosing a subject as suffering from or being at risk of developing Alzheimer's disease, which comprises:
(a) contacting a sample collected from the subject with the antibody of claim 3 ; and
(b) measuring the amount of Aβ oligomer in the sample, wherein the subject is determined to suffer from or be at a risk of developing Alzheimer's disease when the amount measured in (b) is higher than that of a healthy individual.
31. The method of claim 30 , wherein the sample is blood or cerebrospinal fluid.
32. A method of diagnosing a subject as suffering from or being at risk of developing Alzheimer's disease, which comprises the steps of:
(a) contacting a sample collected from the subject with the antibody of claim 3 and an antibody that binds to an Aβ monomer; and
(b) measuring the ratio of Aβ oligomer to Aβ monomer in the sample, wherein the subject is determined to suffer from or be at a risk of developing Alzheimer's disease when the ratio measured in (b) is higher than that of a healthy individual.
33. The method of claim 31 , wherein the sample is blood or cerebrospinal fluid.